Amylyx Pharmaceuticals Inc. | Small-cap | Healthcare
$6.25
-2.50%
| Amylyx Stock Comparison:
Amylyx vs VertexAmylyx vs RegeneronAmylyx vs Vera TherapeuticsAmylyx vs Immunocore HoldingsAmylyx vs AgiosAmylyx vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 87.4M
Gross Profit -37.3M -42.65%
Operating Income -291.9M -334.07%
Net Income -301.7M -345.36%

Balance Sheet Metrics

Total Assets 193.6M
Total Liabilities 28.9M
Shareholders Equity 164.8M
Debt to Equity 0.18

Cash Flow Metrics

Operating Cash Flow -221.6M
Free Cash Flow -167.8M

Revenue & Profitability Trend

Amylyx Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 87.4M 380.8M 22.2M 0 0
Cost of Goods Sold 124.6M 25.4M 3.0M 0 -
Gross Profit -37.3M 355.3M 19.2M 0 -
Operating Expenses 254.6M 316.5M 220.6M 82.7M 39.0M
Operating Income -291.9M 38.8M -201.3M -82.7M -39.0M
Pre-tax Income -302.1M 54.3M -197.6M -87.9M -42.3M
Income Tax -393.0K 5.0M 774.0K 0 -
Net Income -301.7M 49.3M -198.4M -87.9M -42.3M
EPS (Diluted) - $0.70 -$3.39 -$1.59 -$0.92

Income Statement Trend

Amylyx Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 189.4M 464.7M 382.1M 105.0M 13.6M
Non-Current Assets 4.2M 52.8M 9.3M 663.0K 465.0K
Total Assets 193.6M 517.5M 391.5M 105.6M 14.1M
Liabilities
Current Liabilities 28.4M 82.0M 46.6M 17.4M 7.3M
Non-Current Liabilities 463.0K 2.0M 4.2M 239.4M 73.5M
Total Liabilities 28.9M 84.0M 50.8M 256.8M 80.8M
Equity
Total Shareholders Equity 164.8M 433.4M 340.6M -151.2M -66.7M

Balance Sheet Composition

Amylyx Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -301.7M 49.3M -198.4M -87.9M -42.3M
Operating Cash Flow -221.6M 5.1M -198.6M -78.9M -39.0M
Investing Activities
Capital Expenditures -157.0K -1.2M -2.5M -353.0K -151.0K
Investing Cash Flow 75.7M 92.1M -239.0M -46.4M -151.0K
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -1.8M -3.5M 429.6M 158.2M 46.8M
Free Cash Flow -167.8M 10.7M -182.4M -75.2M -36.8M

Cash Flow Trend

Amylyx Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 2.54
Forward P/E -2.71
Price to Book 2.22
Price to Sales -351.80
PEG Ratio -2.71

Profitability Ratios

Profit Margin -42.65%
Operating Margin 16,317.06%
Return on Equity -83.24%
Return on Assets -40.72%

Financial Health

Current Ratio 12.05
Debt to Equity 0.69
Beta -0.59

Per Share Data

EPS (TTM) -$3.10
Book Value per Share $2.26
Revenue per Share -$0.02

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
amlx 447.5M 2.54 2.22 -83.24% -42.65% 0.69
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Vera Therapeutics 1.4B -8.41 2.58 -39.49% 0.00% 10.18
Immunocore Holdings 1.6B -31.41 4.13 -5.86% -6.48% 114.67
Agios 1.9B 2.89 1.32 60.26% 1,798.26% 3.61

Financial data is updated regularly. All figures are in the company's reporting currency.